SpeechDx

The Alzheimer's Drug Discovery Foundation (ADDF) SpeechDx longitudinal study is the first to create the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease through these biomarkers. The recorded voice samples from the study will be combined with clinical and biomarker data to develop algorithms for the creation of new speech biomarkers. The study will last three years and will collect data from 2,650 participants from five different centers, including the BBRC, which will contribute 400 people from the Alfa+ and Beta-AARC cohorts.